<DOC>
	<DOCNO>NCT01065376</DOCNO>
	<brief_summary>The dopamine agonist cabergoline inhibit phosphorylation vascular endothelial growth factor receptor-2 ( VEGFR-2 ) , prevent vascular endothelial growth factor ( VEGF ) overexpression reduce severity Ovarian hyperstimulation syndrome . However , VEGF play important role growth maintenance ovarian follicle develop embryo mediate angiogenesis.This study design analyze whether time cabergoline administration day human chorionic gonadotropin ( hCG ) injection oocytes retrieve affect oocyte maturation outcome assist reproduction treatment .</brief_summary>
	<brief_title>The Influence Dopamine Agonist Cabergoline Oocyte Maturation</brief_title>
	<detailed_description>BACKGROUND : Ovarian hyperstimulation syndrome ( OHSS ) serious complication ovulation induction . It result increase vascular permeability cause ovarian hypersecretion VEGF ) , activate receptor-2 . The dopamine agonist cabergoline inhibit phosphorylation receptor VEGFR-2 , prevent VEGF overexpression reduce severity OHSS . However , VEGF play important role growth maintenance ovarian follicle develop embryo mediating angiogenesis . In human , cabergoline averts OHSS , possible detrimental effect oocyte maturation explore . This study design analyze whether time cabergoline administration day hCG injection oocyte retrieve affect oocyte maturation outcome assist reproduction treatment . PURPOSE : To assess whether time cabergoline administration affect metaphase II oocytes number , embryo quality , pregnancy outcome incidence OHSS . METHODS : A prospective randomized study design evaluate possible cabergoline affect oocyte maturation . Women ( n=120 ) control ovarian hyperstimulation risk OHSS ( Estradiol ( E2 ) &gt; 4000 pg/ml , &gt; 18 follicle , &gt; 11 mm development ) randomize two group . Group I ( n=60 ) receive 0.5 mg oral cabergoline per day 8 day day hCG . Group II ( n=60 ) receive 0.5 mg oral cabergoline per day 8 day day oocyte retrieval immediately . ANTICIPATED RESULTS : No significant difference see number metaphase II oocytes , embryo quality , pregnancy rate incidence OHSS .</detailed_description>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<criteria>risk ovarian hyperstimulation syndrome development allergic cabergoline</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>38 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>IVF</keyword>
	<keyword>OHSS</keyword>
	<keyword>cabergoline</keyword>
</DOC>